Objective: To study the potential effect of Methotrexate (MTX) on lipid peroxidation and activity of glutathione peroxidase (GPx) and superoxide dismutase (SOD) two important endogenous anti-oxidant enzymes.

Methods: Twenty healthy male Newzland rabbits weighting 1500-1800 g were divided into two groups. One group was considered as the MTX groups and the other was considered as control group. Rabbits had free access to food and tap water. Rabbits in MTX group received a single dose of MTX, 20 mg/kg intraperitoneally, a similar volume of saline was administered to control group. After 6 days rabbits were uteinized and spinal tissue excised for biochemical studies.

Results: GPX and SOD activities in spinal tissue in rabbits of MTX group significantly reduced after MTX administration compared to control group(P = 0.002 vs 0.18). An increase in the tissue MDA level was seen in the MTX group, suggesting increased lipid peroxidation. Levels of MDA were significantly higher in MTX group compared to control group (P = 0.002).

Conclusion: Our data suggests that MTX treatment induces oxidative tissue damage on the spinal tissue, as assessed by increased lipid peroxidation and decreased GPX and SOD levels, so decreasing oxidative stress by anti-oxidant agents may play a key role in attenuating spinal cord injury.

Download full-text PDF

Source

Publication Analysis

Top Keywords

mtx group
16
lipid peroxidation
12
control group
12
spinal tissue
12
mtx
9
spinal cord
8
group
8
rabbits mtx
8
gpx sod
8
compared control
8

Similar Publications

Methotrexate (MTX) is an antimetabolite drug utilized for managing a variety of cancers and autoinflammatory conditions. MTX may trigger detrimental effects in mout, h tissues, including salivary gland impairment. Bosentan (BOS), a drug that blocks endothelin receptors, has strengthened antioxidant, anti-inflammatory, and anti-apoptotic properties.

View Article and Find Full Text PDF

Chinese Registry of Rheumatoid Arthritis (CREDIT) VI: Temporal Trends in Patients With Early Rheumatoid Arthritis and Moderate-To-Severe Disease Activity - A Multicenter Cohort Study of Treatment Strategies and Outcomes.

Int J Rheum Dis

January 2025

Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences and Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science and Technology; State Key Laboratory of Complex Severe and Rare Diseases; Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China.

Aim: The continuous update of international guidelines and enhanced availability of biological disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) have made a significant impact on the diagnosis and treatment of early rheumatoid arthritis (ERA). This study aims to systematically evaluate the current treatment strategies and outcomes within a large-scale cohort of patients with ERA.

Methods: Data from the Chinese Registry of Rheumatoid Arthritis (CREDIT), a large multicenter Chinese registry of RA, were collected to analyze temporal trends in clinical profiles, therapeutic strategies, and treatment outcomes among patients with ERA.

View Article and Find Full Text PDF

Methotrexate (MTX) is classified as an antimetabolite. It's commonly used to treat lung cancer. MTX is an immunosuppressant following the above-mentioned mechanism of action due to its poor selectivity.

View Article and Find Full Text PDF

<b>Background and Objective:</b> Methotrexate is an anti-metabolic medication used to treat cancer. It causes oxidative stress in nerve tissue and has neurotoxic effects. A strong antioxidant and effective free radical scavenger is vitamin C.

View Article and Find Full Text PDF

Our previous study highlighted the anticancer potential of sea hare hydrolysate (SHH), particularly its role in regulating macrophage polarization and inducing pyroptotic death in lung cancer cells through the inhibition of signal transducer and activator of transcription 3 (STAT3). These findings prompted us to investigate additional features of immune-oncology (I-O) agents or adjuvants, such as programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibition and their association with rheumatoid arthritis (RA) risk, to explore the potential of SHH as an I-O agent or adjuvant. In this study, we investigated the effects of SHH on PD-L1 levels in various cancer cell types and assessed its effectiveness in treating RA, a common side effect of I-O agents.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!